Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.
Abstract: HBV DNA levels of patients with rtA181S mutation at baseline and emergence of rtA181T + rtN236T double mutation or a wide variety of mutations during combination therapy could not be suppressed.
Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected population.
Discussion: In conclusion, in our study classical antiviral resistance mutations (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-rtM204V/I-rtN236T-rtM
Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran).
PMID: 24064642
2013
Indian journal of medical microbiology
Abstract: Of these, 3 (6.6%) patients had primary resistance mutation (rtM204I, rtA181T and rtA181S) and 20 (44.4%) patients had secondary resistance mutations.
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome.
Discussion: Moreover, rt Discussion: The variation in percentages of rtA181S followed a pattern similar to that of rtA181T, but with a less intense effect (moderately increased after LMV VBK, maintained during ADV, and undetectable after ETV treatment), therefore, position rt181 had a major role in resistance to multiple NAs in the longitudinally followed patient.
Discussion: With this approach, the sensitivity to different NAs of the less common resistant variants (rtV191I, rtA181S, and rtA200V) found among the most variable ones can also be studied.
Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance.
Abstract: In the patients with viral rebound and ADV genotypic resistance, 19 (25.7%) showed rtA181V/T/S + rtN236T substitutions.
Abstract: Seventy-six patients (47.2%) were found to carry the rtA181V/T/S or rtN236T residue substitution, and most of them had viral rebound.
Abstract: The rtN236T was more frequent in patients with genotype B, and the rtA181V/T/S was more common in patients with genotype C (chi(2) = 11.543, P = 0.001).
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs.
Abstract: HBV reverse-transcriptase (RT) region was sequenced and analyzed for 20 mutations, confirmed by in vitro studies as associated with resistance to nucleos(t)ide HBV-RT inhibitors (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-
Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array.
PMID: 21513743
2011
Journal of virological methods
Abstract: A novel polymerase chain reaction (PCR)-Luminex assay was developed for rapid, accurate, and high-throughput detection of the most important hepatitis B virus (HBV) variants, including those with reverse transcriptase (RT) domain L180M, M204I/V, A181T/V/S, I233V and N236T mutations associated with resistance to lamivudine (LAM) or adefovir (ADV).
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Result: Table 4 summarizes the incidence of the purported mutations under different NA treatment schedules, including rtV84M, rtA181T/S (alone), rtV214A, rtQ215S, rtL217R and rtI233V.
Result: The patterns of rtA181T/S together with signature resistance mutations are presented in 2, 3.
Table: A181S
Table: A181T/S
Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients.
PMID: 21056552
2011
Clinica chimica acta; international journal of clinical chemistry
Abstract: Other mutational patterns (rtV173M, rtA181S/V, rtM204I, rtQ215H, rtL229M, rtN238H, rtV84M+rtA181S+rtM204I, rtV84M+rtM204I, rtA181S+ PMID: 20875460
2010
Antiviral research
Abstract: Among the 10 well-characterized N(t)RTI-resistance mutations, L80I/V, V173L, L180M, A181T, T184S, S202G and M204I/V were significantly associated with treatment with lamivudine, an l-nucleoside analog, and A181S/T/V and N236T were significantly associated with treatment with adefovir, an acyclic nucleoside phosphonate.
Result: Twelve mutations at the eight of these 10 positions were significantly associated with N(t)RTI therapy (Fisher's Exact test; Benjamini-Hochberg adjusted p value <0.01): L80I/V, V173L, L180M,
HBV mutation literature information.
PMID: 
2014
Journal of gastroenterology
Browser Board
Co-occurred Entities
Filtrator
ViMRT